BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33972504)

  • 1. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.
    Wang Y; Sinha S; Wellik LE; Secreto CR; Rech KL; Call TG; Parikh SA; Kenderian SS; Muchtar E; Hayman SR; Koehler AB; Van Dyke DL; Leis JF; Slager SL; Dong H; Kay NE; He R; Ding W
    Blood Cancer J; 2021 May; 11(5):86. PubMed ID: 33972504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.
    He R; Ding W; Viswanatha DS; Chen D; Shi M; Van Dyke D; Tian S; Dao LN; Parikh SA; Shanafelt TD; Call TG; Ansell SM; Leis JF; Mai M; Hanson CA; Rech KL
    Am J Surg Pathol; 2018 Jul; 42(7):843-854. PubMed ID: 29762141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 is highly expressed by neoplastic B-cells in Richter transformation.
    Behdad A; Griffin B; Chen YH; Ma S; Kelemen K; Lu X; Chen QC
    Br J Haematol; 2019 Apr; 185(2):370-373. PubMed ID: 30028010
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinicopathological Study of PD-1/PD-L1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with Emphasis on Large B-Cell Richter Transformation.
    Masoud R; Eladl AE; El-Ashwah S; Abbas A; Kandil W
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4243-4252. PubMed ID: 38156860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome.
    Augé H; Notarantonio AB; Morizot R; Quinquenel A; Fornecker LM; Hergalant S; Feugier P; Broséus J
    Front Immunol; 2020; 11():594841. PubMed ID: 33381116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.
    Griffin GK; Weirather JL; Roemer MGM; Lipschitz M; Kelley A; Chen PH; Gusenleitner D; Jeter E; Pak C; Gjini E; Chapuy B; Rosenthal MH; Xu J; Chen BJ; Sohani AR; Lovitch SB; Abramson JS; Ishizuka JJ; Kim AI; Jacobson CA; LaCasce AS; Fletcher CD; Neuberg D; Freeman GJ; Hodi FS; Wright K; Ligon AH; Jacobsen ED; Armand P; Shipp MA; Rodig SJ
    Blood; 2021 Mar; 137(10):1353-1364. PubMed ID: 32871584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.
    Song MK; Park BB; Uhm J
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.
    Klintman J; Appleby N; Stamatopoulos B; Ridout K; Eyre TA; Robbe P; Pascua LL; Knight SJL; Dreau H; Cabes M; Popitsch N; Ehinger M; Martín-Subero JI; Campo E; Månsson R; Rossi D; Taylor JC; Vavoulis DV; Schuh A
    Blood; 2021 May; 137(20):2800-2816. PubMed ID: 33206936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computed tomography textural analysis for the differentiation of chronic lymphocytic leukemia and diffuse large B cell lymphoma of Richter syndrome.
    Reinert CP; Federmann B; Hofmann J; Bösmüller H; Wirths S; Fritz J; Horger M
    Eur Radiol; 2019 Dec; 29(12):6911-6921. PubMed ID: 31236702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.
    Pascual M; Mena-Varas M; Robles EF; Garcia-Barchino MJ; Panizo C; Hervas-Stubbs S; Alignani D; Sagardoy A; Martinez-Ferrandis JI; Bunting KL; Meier S; Sagaert X; Bagnara D; Guruceaga E; Blanco O; Celay J; Martínez-Baztan A; Casares N; Lasarte JJ; MacCarthy T; Melnick A; Martinez-Climent JA; Roa S
    Blood; 2019 May; 133(22):2401-2412. PubMed ID: 30975638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome.
    Fabbri G; Khiabanian H; Holmes AB; Wang J; Messina M; Mullighan CG; Pasqualucci L; Rabadan R; Dalla-Favera R
    J Exp Med; 2013 Oct; 210(11):2273-88. PubMed ID: 24127483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
    McClanahan F; Hanna B; Miller S; Clear AJ; Lichter P; Gribben JG; Seiffert M
    Blood; 2015 Jul; 126(2):203-11. PubMed ID: 25800048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.
    Lewinsky H; Barak AF; Huber V; Kramer MP; Radomir L; Sever L; Orr I; Mirkin V; Dezorella N; Shapiro M; Cohen Y; Shvidel L; Seiffert M; Herishanu Y; Becker-Herman S; Shachar I
    J Clin Invest; 2018 Dec; 128(12):5465-5478. PubMed ID: 30277471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Richter syndrome: A rare complication of chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Wąsik-Szczepanek E; Szymczyk A; Szczepanek D; Wszoła-Kleinrok J; Chocholska S; Pluta A; Hus M
    Adv Clin Exp Med; 2018 Dec; 27(12):1683-1689. PubMed ID: 30156387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway.
    Lenartova A; Randen U; Johannesen TB; Tjønnfjord GE
    Cancer Epidemiol; 2019 Jun; 60():128-133. PubMed ID: 30986631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Richter syndrome in B-cell chronic lymphocytic leukemia.
    Nakamura N; Abe M
    Pathol Int; 2003 Apr; 53(4):195-203. PubMed ID: 12675762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.
    Chigrinova E; Rinaldi A; Kwee I; Rossi D; Rancoita PM; Strefford JC; Oscier D; Stamatopoulos K; Papadaki T; Berger F; Young KH; Murray F; Rosenquist R; Greiner TC; Chan WC; Orlandi EM; Lucioni M; Marasca R; Inghirami G; Ladetto M; Forconi F; Cogliatti S; Votavova H; Swerdlow SH; Stilgenbauer S; Piris MA; Matolcsy A; Spagnolo D; Nikitin E; Zamò A; Gattei V; Bhagat G; Ott G; Zucca E; Gaidano G; Bertoni F
    Blood; 2013 Oct; 122(15):2673-82. PubMed ID: 24004666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients.
    Parikh SA; Rabe KG; Call TG; Zent CS; Habermann TM; Ding W; Leis JF; Schwager SM; Hanson CA; Macon WR; Kay NE; Slager SL; Shanafelt TD
    Br J Haematol; 2013 Sep; 162(6):774-82. PubMed ID: 23841899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy.
    Jamroziak K; Tadmor T; Robak T; Polliack A
    Leuk Lymphoma; 2015 Jul; 56(7):1949-58. PubMed ID: 25356923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
    Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.